4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Fujian Haixi Pharmaceuticals Co., Ltd. (2637) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Fuzhou, China with about 200 employees. Its market capitalization is roughly HKD 15 billion. In the fiscal year ended 2025-12-31, 2637 reported HKD 582M in revenue and HKD 177M in net income.
Fujian Haixi Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical products in China. The company offers drugs for oncology, ophthalmology, respiratory, digestion, cardiovascular, endocrine, and nervous systems, and inflammation.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Revenue | HKD 582M | — |
| Gross Profit | HKD 486M | — |
| Operating Income (EBIT) | HKD 197M | — |
| Net Income | HKD 177M | — |
HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | HKD 1.8B | — | — | — |
| Total Liabilities | HKD 253M | — | — | — |
HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2637 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms